Mechanisms of aortic aneurysm formation: Translating preclinical studies into clinical therapies

Heart

Volumn 100, Issue 19, 2014, Pages 1498-1505

  Davis, Frank M ^a   Rateri, Debra L ^a   Daugherty, Alan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT;

AORTA ANEURYSM; AORTIC RUPTURE; ASYMPTOMATIC DISEASES; COMPLICATION; DISEASE COURSE; DRUG SCREENING; DRUG THERAPY; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; TRANSLATIONAL RESEARCH; TRENDS;

AORTIC ANEURYSM; AORTIC RUPTURE; ASYMPTOMATIC DISEASES; CARDIOVASCULAR AGENTS; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY; HUMANS; METABOLIC PHENOMENA; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84921653721     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-305648     Document Type: Review

References (30)

1. Chaikof EL, Brewster DC, Dalman RL, et al. SVS practice guidelines for the care of patients with an abdominal aortic aneurysm: executive summary. J Vasc Surg 2009;50:880-96.
2. Lederle FA. Ultrasonographic screening for abdominal aortic aneurysms. Ann Intern Med 2003;139:516-22.
3. Moll FL, Powell JT, Fraedrich G, et al. Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery. Eur J Vasc Endovasc Surg 2011;41(Suppl 1):S1-S58.
4. Gillis E, Van Laer L, Loeys BL. Genetics of thoracic aortic aneurysm: at the crossroad of transforming growth factor-beta signaling and vascular smooth muscle cell contractility. Circ Res 2013;113:327-40.
5. Lindsay ME, Dietz HC. Lessons on the pathogenesis of aneurysm from heritable conditions. Nature 2011;473:308-16.
6. Majesky MW. Developmental basis of vascular smooth muscle diversity. Arterioscler Thromb Vasc Biol 2007;27:1248-58.
7. Lu H, Rateri DL, Bruemmer D, et al. Novel mechanisms of abdominal aortic aneurysms. Curr Atheroscler Rep 2012;14:402-12.
8. Thompson RW, Curci JA, Ennis TL, et al. Pathophysiology of abdominal aortic aneurysms: insights from the elastase-induced model in mice with different genetic backgrounds. Ann NY Acad Sci 2006;1085:59-73.
9. Daugherty A, Rateri DL, Charo IF, et al. Angiotensin II infusion promotes ascending aortic aneurysms: attenuation by CCR2 deficiency in apoE-/- mice. Clin Sci (Lond) 2010;118:681-9.
10. Golledge AL, Walker P, Norman PE, et al. A systematic review of studies examining inflammation associated cytokines in human abdominal aortic aneurysm samples. Dis Markers 2009;26:181-8.
11. Wang Y, Ait-Oufella H, Herbin O, et al . TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest 2010;120:422-32.
12. Sharma AK, Lu G, Jester A, et al. Experimental abdominal aortic aneurysm formation is mediated by IL-17 and attenuated by mesenchymal stem cell treatment. Circulation 2012;126:S38-45.
13. Johnston WF, Salmon M, Su G, et al. Genetic and pharmacologic disruption of interleukin-1beta signaling inhibits experimental aortic aneurysm formation. Arterioscler Thromb Vasc Biol 2013;33:294-304.
14. Longo GM, Xiong W, Greiner TC, et al. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002;110:625-32.
15. Sweeting MJ, Thompson SG, Brown LC, et al. Meta-analysis of individual patient data to examine factors affecting growth and rupture of small abdominal aortic aneurysms. Br J Surg 2012;99:655-65.
16. Lindeman JH, Abdul-Hussien H, van Bockel JH, et al. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation 2009;119:2209-16.
17. Meijer CA, Stijnen T, Wasser MN, et al. Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. Ann Intern Med 2013;159:815-23.
18. Sweeting MJ, Thompson SG, Brown LC, et al. Use of angiotensin converting enzyme inhibitors is associated with increased growth rate of abdominal aortic aneurysms. J Vasc Surg 2010;52:1-4.
19. Thompson A, Cooper JA, Fabricius M, et al. An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance. J Vasc Surg 2010;52:55-61.
20. Iida Y, Xu B, Xuan H, et al. Peptide inhibitor of CXCL4-CCL5 heterodimer formation, MKEY, inhibits experimental aortic aneurysm initiation and progression. Arterioscler Thromb Vasc Biol 2013;33:718-26.
21. Maegdefessel L, Azuma J, Toh R, et al. Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J Clin Invest 2012;122:497-506.
22. Kim CW, Kumar S, Son DJ, et al. Prevention of abdominal aortic aneurysm by anti-microRNA-712 or anti-microRNA-205 in angiotensin II-infused mice. Arterioscler Thromb Vasc Biol 2014;34:1412-21.
23. Yoshimura K, Aoki H, Ikeda Y, et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 2005;11:1330-8.
24. Chau KH, Elefteriades JA. Natural history of thoracic aortic aneurysms: size matters, plus moving beyond size. Prog Cardiovasc Dis 2013;56:74-80.
25. Lemaire SA, McDonald ML, Guo DC, et al. Genome-wide association study identi fies a susceptibility locus for thoracic aortic aneurysms and aortic dissections spanning FBN1 at 15q21.1. Nat Genet 2011;43:996-1000.
26. Chen X, Lu H, Rateri DL, et al. Conundrum of angiotensin II and TGF-beta interactions in aortic aneurysms. Curr Opin Pharmacol 2013;13:180-5.
27. Habashi JP, Doyle JJ, Holm TM, et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 2011;332:361-5.
28. Holm TM, Habashi JP, Doyle JJ, et al. Noncanonical TGFbeta signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 2011;332:358-61.
29. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the ACCF/AHA Task Force on Practice Guidelines, AATS, ACR, ASA, SCA, SCAI, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010;121:e266-369.
30. Brooke BS, Habashi JP, Judge DP, et al. Angiotensin II blockade and aortic-root dilation in Marfan 's syndrome. N Engl J Med 2008;358:2787-95.